CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
Total revenue	$ 114,305	$ 52,465	$ 211,155	$ 94,019
Cost of revenue:
Total cost of revenue	45,044	15,724	81,932	28,512
Gross profit	69,261	36,741	129,223	65,507
Operating expenses:
Research, development and clinical trials	13,858	8,291	25,238	14,162
Selling, general and administrative	42,895	29,356	79,056	54,340
Total operating expenses	56,753	37,647	104,294	68,502
Income (loss) from operations	12,508	(906)	24,929	(2,995)
Other income (expense):
Interest expense	(3,623)	(2,505)	(7,221)	(3,596)
Interest income and other income (expense)	3,268	2,431	6,838	2,986
Total other expense, net	(355)	(74)	(383)	(610)
Income (loss) before income taxes	12,153	(980)	24,546	(3,605)
(Provision) benefit for income taxes	41	(21)	(155)	(32)
Net income (loss)	$ 12,194	$ (1,001)	$ 24,391	$ (3,637)
Net income (loss) per share, basic	$ 0.37	$ (0.03)	$ 0.74	$ (0.11)
Net income (loss) per share, diluted	$ 0.35	$ (0.03)	$ 0.7	$ (0.11)
Weighted average common shares outstanding, basic	33,119,514	32,545,352	32,939,852	32,403,597
Weighted average common shares outstanding, diluted	35,288,308	32,545,352	34,983,603	32,403,597
Net product revenue [Member]
Revenue:
Total revenue	$ 71,732	$ 42,462	$ 133,057	$ 76,455
Cost of revenue:
Total cost of revenue	14,470	8,558	28,554	15,864
Service Revenue [Member]
Revenue:
Total revenue	42,573	10,003	78,098	17,564
Cost of revenue:
Total cost of revenue	$ 30,574	$ 7,166	$ 53,378	$ 12,648